Fig 1.
The flowchart of analysis.
Fig 2.
Analysis for the correlation of Elecsys and Lumipulse PIVKA-II assays.
(A) The X-axis shows the Elecsys/Lumipulse ratio, and the Y-axis shows the number of samples. (B) Comparison of Elecsys and Lumipulse assays for the measurement of serum PIVKA-Ⅱ concentration. (1) All patients, (2) patients treated with atezolizumab and bevacizumab (ATZ+BEV), and (3) patients treated with molecular targeted agents (MTAs).
Table 1.
Clinical characteristics of patients with advanced HCC at baseline.
Fig 3.
Cumulative progression-free survival (PFS) rates of advanced HCC patients treated by systemic therapy depending on Elecsys PIVKA-II response at first month.
Table 2.
Clinical characteristics of PIVKA-Ⅱ responders and non-responders.